Psoriasis

Jul 2018 | Assessment

Interventions of Interest: Anti IL-23 agents: Guselkumab (Tremfya®, Janssen/Johnson & Johnson), tildrakizumab (Ilumya™, Sun Pharma), risankizumab (Skyrizi®, AbbVie) Anti TNF agent: Certolizumab pegol (Cimzia®, UCB) Plaque psoriasis is a common disease that causes red, scaly, raised lesions on the skin, most commonly on the elbows, knees, scalp, and back. Psoriasis affects about 2% of the […]

Psoriasis

Nov 2016 | Assessment

Interventions of interest: Anti TNF agents: Adalimumab (Humira®, AbbVie), etanercept (Enbrel®, Amgen, Inc.), infliximab (Remicade®, Janssen) Anti IL-17A agents: Secukinumab (Cosentyx®, Novartis), ixekizumab (Taltz®, Eli Lilly and Co.), brodalumab (SiliqTM, Valeant Pharmaceuticals and AstraZeneca) Anti IL-12/23 agent: Ustekinumab (Stelara®, Janssen) Anti PDE4 agent: Apremilast (Otezla®, Celgene) Plaque psoriasis is a common disease that causes red, scaly, raised lesions on […]

Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis

Journal Article

Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis Background: The comparative effectiveness of available targeted immunomodulators for moderate-to- severe psoriasis has not been evaluated. Objective: To evaluate the comparative effectiveness of targeted immunomodulators for adults with moderate-to-severe plaque psoriasis. Methods: Systematic literature review of placebo-controlled […]

Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis

Journal Article

Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis BACKGROUND: Newer classes of targeted drugs for moderate to severe plaque psoriasis are more effective and more expensive than older classes, posing a difficult and potentially costly decision about whether to use them as initial targeted treatments. OBJECTIVE: To estimate the clinical and economic outcomes […]

Institute for Clinical and Economic Review Updated Report on Targeted Treatments for Plaque Psoriasis Finds Guselkumab and Risankizumab Offer Superior Health Benefit Compared with TNFα Inhibitors

Press Release

— Policy recommendations repeat call for insurers to minimize step therapy requirements on these treatments that are priced in alignment with clinical benefits, but cautions manufacturers against the ongoing price increases that are beginning to threaten the cost-effectiveness of entire therapy class — Boston – August 3, 2018 – The Institute for Clinical and Economic Review […]

Institute for Clinical and Economic Review’s Updated Assessment of New Targeted Therapies for Plaque Psoriasis Notes Minor Distinctions in Effectiveness, While Recent Price Hikes Have Made Entire Drug Class Less Cost-Effective

Press Release

 –Value-based price benchmarks for new IL-23 agents range from $25,000-$42,000 per year, which would require a discount of 37%-57% from the list price of guselkumab, the only drug in this group currently priced in the market — BOSTON – June 12, 2018 – The Institute for Clinical and Economic Review (ICER) today released a condition update report assessing […]

Institute for Clinical and Economic Review Releases Draft Condition Update Report on Treatments for Plaque Psoriasis

Press Release

– Public comment period now open until May 25th; Requests to make oral comment during public meeting also being accepted – BOSTON, April 27, 2018 – The Institute for Clinical and Economic Review (ICER) today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of treatments for moderate-to-severe plaque psoriasis. The review will be open […]

Institute for Clinical and Economic Review Posts Draft Scoping Documents for Two Reviews: CGRP Inhibitors for Migraine and Update to Prior Review of Plaque Psoriasis Treatments

Press Release

  –Documents open to public comment until December 22, 2017–  BOSTON, December 4, 2017– The Institute for Clinical and Economic Review (ICER) has posted two Draft Scoping Documents for public comment. One document outlines ICER’s review of the comparative clinical effectiveness and value of three calcitonin gene-related peptide (CGRP) inhibitors for prevention of migraine. The second outlines […]

Institute for Clinical and Economic Review to Assess Erenumab for Migraine Prevention; Guselkumab and Tildrakizumab for Plaque Psoriasis 

Press Release

–Open Input now being accepted on both topics; Both reviews to be subject to public deliberation at upcoming CTAF meeting– BOSTON, November 9, 2017 – The Institute for Clinical and Economic Review(ICER) will assess the comparative clinical effectiveness and value of erenumab (Amgen/Novartis) for prevention of migraine headaches. The FDA’s decision on whether to approve erenumab is […]

ICER’s Final Report on Targeted Immunomodulators for Plaque Psoriasis Offers Guidance for Policy and Practice

Press Release

Independent CEPAC votes on value and subsequent policy roundtable discussion suggest that drug prices after rebates align well with added value for patients and therefore insurers should consider limiting or abolishing step therapy coverage policies Boston, Mass., December 2, 2016– The Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report and Meeting Summary  […]